GFS Advisors LLC lowered its position in shares of Astrazeneca PLC (NYSE:AZN) by 17.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,633 shares of the company’s stock after selling 8,830 shares during the period. GFS Advisors LLC’s holdings in Astrazeneca PLC were worth $1,419,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Meeder Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter worth approximately $105,000. Salem Investment Counselors Inc. bought a new position in Astrazeneca PLC during the first quarter worth approximately $107,000. Tower Research Capital LLC TRC increased its position in Astrazeneca PLC by 3,782.0% in the first quarter. Tower Research Capital LLC TRC now owns 3,882 shares of the company’s stock worth $121,000 after buying an additional 3,782 shares during the period. Parallel Advisors LLC increased its position in Astrazeneca PLC by 27.1% in the first quarter. Parallel Advisors LLC now owns 4,526 shares of the company’s stock worth $138,000 after buying an additional 964 shares during the period. Finally, Westport Asset Management Inc. bought a new position in Astrazeneca PLC during the second quarter worth approximately $170,000. Hedge funds and other institutional investors own 14.30% of the company’s stock.

Astrazeneca PLC (AZN) opened at 29.42 on Friday. The firm’s 50-day moving average is $31.20 and its 200 day moving average is $31.52. The firm has a market cap of $74.49 billion, a PE ratio of 19.30 and a beta of 0.74. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. Astrazeneca PLC also saw unusually large options trading on Wednesday. Stock investors purchased 8,259 put options on the company. This represents an increase of 1,510% compared to the average daily volume of 513 put options.

Astrazeneca PLC (NYSE:AZN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The company had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period last year, the company earned $0.83 earnings per share. The firm’s revenue was down 9.9% compared to the same quarter last year. On average, equities analysts forecast that Astrazeneca PLC will post $1.86 earnings per share for the current fiscal year.

The business also recently disclosed a None dividend, which will be paid on Monday, September 11th. Stockholders of record on Friday, August 11th will be given a dividend of $0.44 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s dividend payout ratio (DPR) is 44.92%.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/25/astrazeneca-plc-azn-shares-sold-by-gfs-advisors-llc.html.

A number of analysts have weighed in on the stock. Piper Jaffray Companies reissued a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, August 9th. BidaskClub cut shares of Astrazeneca PLC from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Cowen and Company reissued a “hold” rating and set a $34.00 target price on shares of Astrazeneca PLC in a report on Friday, July 28th. Morgan Stanley cut shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Finally, Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eleven have issued a buy rating to the stock. Astrazeneca PLC has an average rating of “Hold” and an average target price of $33.39.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.